Fresenius Kabi to acquire a 55% stake in mAbxience for €495m.

Fresenius Kabi, a pharmaceutical company, agreed to acquire a 55% stake in mAbxience, a high growth international biotechnology company, for €495m. "Expanding our MedTech business and broadening our presence in Biopharmaceuticals are key to our Vision 2026 program. Today’s announcements fit squarely into our plans. With the acquisition of Ivenix, we add the next generation infusion therapy platform; we complement and strengthen our existing infusion therapy offering and we create a superior portfolio for the US market. With mAbxience, we are making a step-change in our biopharmaceuticals profile. This is a highly complementary transaction in terms of biologics pipeline, manufacturing capabilities and the business model. mAbxience is two businesses in one company. mAbxience and Ivenix as portfolio advancements are good for patients, good for healthcare providers and our company," Michael Sen, Fresenius Kabi CEO.